Prognostic utility of BRAF mutation in papillary thyroid cancer
M Xing - Molecular and cellular endocrinology, 2010 - Elsevier
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
Prognostic utility of BRAF mutation in papillary thyroid cancer
M Xing - Molecular and cellular endocrinology, 2010 - pubmed.ncbi.nlm.nih.gov
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
Prognostic utility of BRAF mutation in papillary thyroid cancer
M Xing - Molecular and Cellular Endocrinology, 2010 - pure.johnshopkins.edu
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
[引用][C] Prognostic utility of BRAF mutation in papillary thyroid cancer
M XING - Mol Cell Endocrinol, 2010 - cir.nii.ac.jp
Prognostic utility of BRAF mutation in papillary thyroid cancer | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
[HTML][HTML] Prognostic Utility of BRAF Mutation in Papillary Thyroid Cancer
M Xing - Molecular and cellular endocrinology, 2010 - ncbi.nlm.nih.gov
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
Prognostic utility of BRAF mutation in papillary thyroid cancer
M Xing - Molecular and Cellular Endocrinology, 2010 - hero.epa.gov
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
Prognostic utility of BRAF mutation in papillary thyroid cancer
M Xing - Molecular and Cellular Endocrinology, 2010 - infona.pl
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
Prognostic utility of BRAF mutation in papillary thyroid cancer.
M Xing - Molecular and Cellular Endocrinology, 2009 - europepmc.org
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
Prognostic utility of BRAF mutation in papillary thyroid cancer.
M Xing - Molecular and Cellular Endocrinology, 2009 - europepmc.org
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
[引用][C] Prognostic utility of BRAF mutation in papillary thyroid cancer
M Xing - Molecular and Cellular Endocrinology, 2010 - cir.nii.ac.jp